Implementation of TRIPS and Access to Medicines for HIV after January 2016: Strategies and Options for Least Developed Countries
This document seeks to analyse how LDCs have utilized the 2016 extension to facilitate the production and access to HIV and other medicines for their populations; discuss what can be done to maximize the opportunities provided by the current extensions; describe the potential implications of LDCs having to implement the TRIPS Agreement with respect to pharmaceuticals and test data protection; fill the gaps in the understanding of the process for further extension of the transition period for pharmaceutical products; and provide recommendations on how LDCs should proceed to seek further extensions.
Related feature storiesWorld leaders unite towards ending the AIDS epidemic among adolescents
29 September 2014Leaving no one behind in the post-2015 development agenda: young marginalized people claim their space
26 September 2014Action on sexual and reproductive health and rights critical say leaders
24 September 2014